191 related articles for article (PubMed ID: 38791966)
21. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.
Shibata T; Kokubu A; Gotoh M; Ojima H; Ohta T; Yamamoto M; Hirohashi S
Gastroenterology; 2008 Oct; 135(4):1358-1368, 1368.e1-4. PubMed ID: 18692501
[TBL] [Abstract][Full Text] [Related]
22. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
24. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
25. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma.
Mahaffey CM; Zhang H; Rinna A; Holland W; Mack PC; Forman HJ
Free Radic Biol Med; 2009 Jun; 46(12):1650-7. PubMed ID: 19345732
[TBL] [Abstract][Full Text] [Related]
26. p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway.
Liao W; Wang Z; Fu Z; Ma H; Jiang M; Xu A; Zhang W
Free Radic Res; 2019 Jul; 53(7):800-814. PubMed ID: 31223046
[TBL] [Abstract][Full Text] [Related]
27. PDCD4 inhibits lung tumorigenesis by the suppressing p62-Nrf2 signaling pathway and upregulating Keap1 expression.
Hwang SK; Jeong YJ; Chang YC
Am J Cancer Res; 2020; 10(2):424-439. PubMed ID: 32195018
[TBL] [Abstract][Full Text] [Related]
28. MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis.
Tong Q; Ouyang S; Chen R; Huang J; Guo L
Am J Cancer Res; 2019; 9(9):1938-1956. PubMed ID: 31598396
[TBL] [Abstract][Full Text] [Related]
29. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
30. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
31. Constitutive Activation of Nrf2 in Mice Expands Enterogenesis in Small Intestine Through Negative Regulation of Math1.
Yagishita Y; McCallum ML; Kensler TW; Wakabayashi N
Cell Mol Gastroenterol Hepatol; 2021; 11(2):503-524. PubMed ID: 32896624
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
[TBL] [Abstract][Full Text] [Related]
34.
Akdemir B; Nakajima Y; Inazawa J; Inoue J
Mol Cancer Res; 2017 Nov; 15(11):1570-1578. PubMed ID: 28760781
[TBL] [Abstract][Full Text] [Related]
35. A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T; Tian X; Liu Q; Qiu D; Hancock M; Wu JH; Batist G
Cell Rep; 2023 Sep; 42(9):113104. PubMed ID: 37703174
[TBL] [Abstract][Full Text] [Related]
36. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
37. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
38. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.
Eades G; Yang M; Yao Y; Zhang Y; Zhou Q
J Biol Chem; 2011 Nov; 286(47):40725-33. PubMed ID: 21926171
[TBL] [Abstract][Full Text] [Related]
39. NRF2-Driven
Tian Y; Liu Q; Yu S; Chu Q; Chen Y; Wu K; Wang L
Mol Cancer Res; 2020 Oct; 18(10):1465-1476. PubMed ID: 32571982
[TBL] [Abstract][Full Text] [Related]
40. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
